INTRODUCTION {#S1}
============

Enteroendocrine cells (EECs) are specialized epithelial cells of the gastrointestinal tract that form the largest endocrine system in the body. By sensing luminal signals, EECs produce and secret neurotransmitters and hormones to modulate a variety of metabolic functions locally and systemically, such as gut motility, nutrient intake and absorption, glucose metabolism, lipid homeostasis, and energy balance ([@R42]; [@R43]; [@R28]; [@R21]). Studies suggest that defects in EEC function and gut hormone secretion are associated with human obesity and diabetes ([@R68]; [@R74]; [@R15]). Therefore, gut hormones are excellent therapeutic candidates for treatment of metabolic diseases. Agonists of the glucagonlike peptide 1 (GLP-1) receptor and inhibitors of dipeptidyl peptidase-4 (DPP4), which inactivates GLP-1, are widely used for effective glycemic control in diabetic patients, with demonstrated benefits of weight loss and cardioprotection as well ([@R8]; [@R13]). The gut hormone responses to bariatric procedures have been proposed to be a mechanism for weight loss and improvement in glucose metabolism after surgery ([@R31]). Moreover, dual and triple gut hormone receptor agonists are considered next-generation therapies for metabolic diseases ([@R72]; [@R7]). Despite extensive application of enteroendocrine hormones in the clinic, the pathophysiological regulation of EEC development and function is incompletely understood, and direct means to modulate EEC differentiation *in vivo* are still largely lacking.

Traditionally, EECs are classified on the basis of the hormones they produce: L cells (GLP-1 and peptide YY \[PYY\]), K cells (gastric inhibitory polypeptide \[GIP\]), I cells (cholecystokinin \[CCK\]), D cells (somatostatin \[SST\]), S cells (secretin \[SCT\]), and enterochromaffin (EC) cells (serotonin \[5-HT\]) ([@R38]). However, substantial data from recent studies using transcriptional profiling, transgenic reporter lines, immunohistochemistry, and particularly single-cell RNA sequencing have demonstrated that there is significant coexpression of hormones and crossover between EEC subtypes ([@R14]; [@R23]; [@R21]; [@R22]; [@R18]). EECs differentiate from the common LGR5^+^ pluripotent stem cells in the base of the crypt compartment ([@R11]; [@R4]). Three basic helix-loop-helix transcription factors, including ATOH1, Neurogenin 3 (encoded by the *Ngn3* gene), and NeuroD1, are expressed sequentially and function in cascades for EEC differentiation ([@R61]). ATOH1 is critical for development of all three secretory cell types ([@R80]; [@R65]), whereas Neurogenin 3 is specific for determination and differentiation into EECs ([@R32]; [@R39]; [@R42]). NeuroD1, a downstream target of Neurogenin 3, is important for S and I cell differentiation ([@R44]; [@R46]). In addition, PAX4 and PAX6 have been shown to control L, K, D, and EC cell differentiation ([@R37]). Recently, novel general and lineage-specific regulators of EEC differentiation have also been identified by real-time single-cell transcriptional profiling ([@R18]). Nonetheless, the upstream molecular mechanisms fine-tuning the transcriptional machinery for EEC development have not been fully elucidated.

Within the last three decades, it was discovered that thousands of cytoplasmic and nuclear proteins are modified by a single O-linked β-N-acetylglucosamine (O-GlcNAc) moiety at serine or threonine residues, termed O-GlcNAcylation ([@R70]; [@R25], [@R26]). O-GlcNAcylation is radically different from other types of glycosylation and, analogous to phosphorylation, plays a central role in signaling pathways relevant to normal cell physiology and chronic human diseases, including cardiovascular disease, diabetes, neurodegeneration, and cancer ([@R5]; [@R58]; [@R79]). The enzymes O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) mediate addition and removal of O-GlcNAc, respectively ([@R75]; [@R33]). O-GlcNAc signaling acts as a hormone and nutrient sensor to control many biological processes, such as gene transcription, translation, protein stability and folding, and cell signaling ([@R24]; [@R56], [@R57], [@R59], [@R60]; [@R40]). Recently, we found that, in the intestinal epithelium, levels of protein O-GlcNAcylation are reduced in patients with inflammatory bowel disease and showed that OGT is required for survival of intestinal epithelial cells and their interplay with gut microbiota ([@R83]). Here we further determined that intestinal epithelial O-GlcNAcylation is sensitive to microbiota-derived short-chain fatty acids, controls EEC lineage differentiation and function, and regulates systemic energy and glucose metabolism.

RESULTS {#S2}
=======

Deficiency in Intestinal Epithelial OGT Promotes L Cell Differentiation and Metabolic Health in Mice {#S3}
----------------------------------------------------------------------------------------------------

To determine whether protein O-GlcNAcylation negatively controls EEC development, we genetically deleted OGT specifically in intestinal epithelial cells (*Vil-Ogt* knockout \[KO\]) by crossing the *Villin-Cre* and *Ogt-floxed* mouse lines ([@R59]; [@R83]). The *Ogt* gene is located on the X chromosome; thus, male mice are hemizygous. Levels of *Ngn3* and various gut hormone genes, including *Gcg* (L cells), *Gip* (K cells), and *Cck* (I cells), were elevated in the ileum and colon of *Vil-Ogt* KO males compared with littermate controls ([Figures 1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}). Segment-specific changes were also observed. For example, *Pax6* and the EC cell marker *Chga* were only increased in the *Vil-Ogt* KO ileum ([Figure 1A](#F1){ref-type="fig"}). Expression of the L cell-specific regulator *Hoxb9* and the hormone *Pyy* was upregulated in the colon of *Vil-Ogt* KO mice ([Figure 1B](#F1){ref-type="fig"}). We then specifically examined L cells and found that GLP-1^+^ and PYY^+^ cell numbers in the intestine ([Figures 1C](#F1){ref-type="fig"}--[1E](#F1){ref-type="fig"}) and GLP-1 levels in the serum ([Figure 1F](#F1){ref-type="fig"}) were increased in *Vil-Ogt* KO males.

Concomitantly, hemizygous *Vil-Ogt* KO male mice showed lower body weight ([Figure 2A](#F2){ref-type="fig"}), less fat and lean mass ([Figure 2B](#F2){ref-type="fig"}), decreased random blood glucose ([Figure 2C](#F2){ref-type="fig"}), and enhanced glucose clearance rate during an oral glucose tolerance test ([Figures 2D](#F2){ref-type="fig"} and [2E](#F2){ref-type="fig"}) compared with littermate control males. Similarly, homozygous *Vil-Ogt* KO females also had decreased body weight ([Figure 2F](#F2){ref-type="fig"}) and improved glucose tolerance ([Figures 2G](#F2){ref-type="fig"} and [2H](#F2){ref-type="fig"}). Collectively, these data demonstrate that OGT deficiency in the intestinal epithelium promotes enteroendocrine L cell development and improves body weight and glucose metabolism.

A Cell-Autonomous Action of O-GlcNAcylation on L Cell Development {#S4}
-----------------------------------------------------------------

*Vil-Ogt* KO mice develop intestinal damage and inflammation ([@R83]), which may confound our findings regarding L cell development. We then performed *ex vivo* intestinal organoid culture and found that OGT inhibition by OSMI-1 decreased global protein O-GlcNAcylation ([@R49]; [Figure S1A](#SD1){ref-type="supplementary-material"}); increased the expression of *Ngn3, Hoxb9,* and the L cell hormone genes *Gcg* and *Pyy* ([Figure 3A](#F3){ref-type="fig"}); and notably enhanced GLP-1 secretion from organoids ([Figure 3B](#F3){ref-type="fig"}).

To extend these findings *in vivo*, we then specifically overexpressed OGT in intestinal epithelial cells by crossing *Villin-Cre* with a mouse line harboring an inducible rat OGT transgene in the *Rosa26* locus ([@R81]; [Figure 3C](#F3){ref-type="fig"}). qRT-PCR showed that expression of the rat *Ogt* gene was significantly up-regulated in intestinal tissues ([Figure 3D](#F3){ref-type="fig"}). Immunoblotting further confirmed OGT overexpression and elevation of global protein O-GlcNAcylation ([Figure 3E](#F3){ref-type="fig"}). Inflammatory gene expression and intestinal epithelial permeability were comparable in control and *Vil-Cre*^+^*;R26-rOGT* mice ([Figures S1B](#SD1){ref-type="supplementary-material"}--[S1D](#SD1){ref-type="supplementary-material"}), suggesting that OGT overexpression did not overtly cause epithelial damage or inflammation. As expected, *Vil-Cre*^+^*;R26-rOGT* mice displayed reduced L cell numbers in the colon ([Figures 3F](#F3){ref-type="fig"} and [3G](#F3){ref-type="fig"}) and GLP-1 levels in the serum ([Figure 3H](#F3){ref-type="fig"}) compared with controls. Although similar body weight ([Figure 3I](#F3){ref-type="fig"}) and fasting glucose levels ([Figure 3J](#F3){ref-type="fig"}) were observed in controls and *Vil-Cre*^+^*;R26-rOGT* mice, *Vil-Cre*^+^*;R26-rOGT* mice had higher fasting insulin levels in the blood ([Figure 3K](#F3){ref-type="fig"}) and showed a trending increase in homeostatic model assessment of insulin resistance (HOMA-IR, [Figure 3L](#F3){ref-type="fig"}). These results demonstrate that OGT and protein O-GlcNAcylation negatively regulate L cell development and glucose metabolism in a cell-autonomous manner.

OGT Suppresses *Ngn3* Gene Transcription via FOXO1 O-GlcNAcylation {#S5}
------------------------------------------------------------------

NGN3 plays a pivotal role in controlling the commitment of pluripotent progenitor cells toward the EEC lineage ([@R32]; [@R42]). We could not detect O-GlcNAcylation of overexpressed NGN3 ([Figure S2A](#SD1){ref-type="supplementary-material"}); thus we sought to test whether OGT controls *Ngn3* gene transcription. Consistent with the observation that the expression of *Ngn3* and its downstream genes was upregulated in *Vil-Ogt* KO intestine ([Figures 1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}), OGT was able to suppress *Ngn3* promoter activity in cultured cells ([Figure 4A](#F4){ref-type="fig"}). Previous reports have shown that FOXO1, an O-GlcNAc-modified protein, negatively regulates *Ngn3* transcription ([@R1]; [@R6]). We sought to test whether OGT represses *Ngn3* transcription via FOXO1 O-GlcNAcylation. Consistent with previous reports ([@R29]; [@R16]), we found that OGT overexpression ([Figure 4B](#F4){ref-type="fig"}) and specific inhibition of OGA by 6-Ac-CAS ([Figure 4C](#F4){ref-type="fig"}) substantially increased FOXO1's transactivation activity on insulin-responsive elements. We then mutated four known O-GlcNAc sites on FOXO1 (T314, S547, T645, and S651) to alanine (FOXO1-4A) ([@R29]). FOXO1-4A showed impairment in O-GlcNAcylation compared with wild-type FOXO1, particularly when OGA was inhibited by PUGNAc ([Figure 4D](#F4){ref-type="fig"}). As a result, the 4A mutation diminished the transcriptional activator function of FOXO1 when co-expressed with OGT ([Figure 4E](#F4){ref-type="fig"}).

On the other hand, FOXO1 acted as a transcriptional repressor on the *Ngn3* promoter ([Figure 4F](#F4){ref-type="fig"}), and such inhibitory activity was absent when FOXO1 O-GlcNAcylation was ablated ([Figure 4F](#F4){ref-type="fig"}). To test whether the effect of OGT on L cell development is dependent on FOXO1, we treated ileal organoids with the OGT inhibitor OSMI-1 in the presence or absence of a FOXO1 inhibitor, AS1842856. Regarding FOXO1's positive target genes, such as *Gopc,* suppression oi transcription by OSMI-1 was abolished when AS1842856 was present ([Figure S2B](#SD1){ref-type="supplementary-material"}). Notably, the ability of OGT inhibition by OSMI-1 to promote expression of *Ngn3, Gcg,* and *Pyy* genes ([Figure 4G](#F4){ref-type="fig"}--[I](#F4){ref-type="fig"}) and secretion of GLP-1 ([Figure 4J](#F4){ref-type="fig"}) was diminished when the transcriptional activity of FOXO1 was blocked by AS1842856. Together, these results suggest that FOXO1 O-GlcNAcylation mediates the transcriptional suppression of the *Ngn3* gene by OGT.

OGT in the *Ngn3* Lineage Controls Differentiation of L Cells {#S6}
-------------------------------------------------------------

Next we sought to determine whether O-GlcNAc signaling in *Ngn3*^+^ progenitors controls L cell differentiation. To do so, we generated EEC-specific OGT KO mice using the *Ngn3-Cre* line ([@R62]). No changes in body weight were observed between wild-type and *Ngn3-Ogt* KO mice ([Figure 5A](#F5){ref-type="fig"}). Pancreatic endocrine progenitors also express *Ngn3,* and deletion of OGT in islet progenitors (E.U.A., unpublished data) or insulin^+^ cells ([@R2]) induces diabetes as a result of β-cell dysfunction as early as 4 weeks of age ([Figures 5B](#F5){ref-type="fig"} and [S3A](#SD1){ref-type="supplementary-material"}). Therefore, we analyzed *Ngn3-Ogt* KO mice before weaning, when they had similar body weight, slightly lower blood glucose ([Figure 5A](#F5){ref-type="fig"}, [B](#F5){ref-type="fig"}), and normal β-cell mass in *Ngn3-Ogt* KO compared with littermate controls (E.U.A., unpublished data). Immunostaining showed that GLP-1^+^ and PYY^+^ L cells ([Figures 5C](#F5){ref-type="fig"} and [5D](#F5){ref-type="fig"}) and ChgA^+^ EC cells ([Figures S3B](#SD1){ref-type="supplementary-material"} and [S3C](#SD1){ref-type="supplementary-material"}) modestly increased their numbers in the *Ngn3-Ogt* KO intestine. At this age, when assessed for oral glucose tolerance, *Ngn3-Ogt* KO mice had higher initial blood glucose levels, probably because of defects in β-cells, but faster glucose clearance, which could be attributed to GLP-1-mediated insulin hypersensitivity ([Figure 5E](#F5){ref-type="fig"}).

To eliminate potential confounding effects from *Ngn3*-expressing pancreas and neurons, we isolated and cultured ileal organoids from control and *Ngn3-Ogt* KO mice to assess L cell development. qPCR revealed no changes in the expression of markers for enterocytes (*Slc5a1*), goblet cells (*Muc2*), Paneth cells (*Defa6*), or tuft cells (*Dclk1*) ([Figure S3D](#SD1){ref-type="supplementary-material"}). Among EEC marker genes, L cell-specific *Hoxb9, Gcg,* and *Pyy* were significantly upregulated in *Ngn3-Ogt* KO organoids, whereas *Ngn3* and genes encoding other EEC hormones were unaffected ([Figures 5F](#F5){ref-type="fig"} and [S3E](#SD1){ref-type="supplementary-material"}). As a result, more GLP-1 peptides could be detected in the medium of *Ngn3-Ogt* KO organoids than in a wild-type culture ([Figure 5G](#F5){ref-type="fig"}). OGT inhibition by OSMI-1 and *Ngn3-Ogt* KO significantly increased the number of GLP-1^+^ cells ([Figures 5H](#F5){ref-type="fig"} and [4I](#F4){ref-type="fig"}; [Table S1](#SD2){ref-type="supplementary-material"}). However, OSMI-1 could not further promote L cell hyperplasia in *Ngn3-Ogt* KO organoids ([Figures 5H](#F5){ref-type="fig"} and [5I](#F5){ref-type="fig"}), suggesting that OSMI-1 acted on *Ngn3*^+^ EEC progenitors to promote L cell development.

Protein O-GlcNAcylation and L Cell Function Are Inversely Regulated {#S7}
-------------------------------------------------------------------

Nutrients like glucose and fatty acids drive the hexosamine synthetic pathway and protein O-GlcNAcylation. We then sought to test whether levels of intestinal epithelial O-GlcNAcylation are regulated by food availability. Overnight fasting in mice significantly reduced the level of global protein O-GlcNAcylation in colonic epithelial cells, which was replenished by 4 h of refeeding ([Figure 6A](#F6){ref-type="fig"}). In rodents, high-fat diet (HFD)-induced obesity impairs L cell function ([@R19]; [@R54]; [@R84]). However, we found that intestinal protein O-GlcNAcylation was substantially increased by HFD in mice ([Figure 6B](#F6){ref-type="fig"}).

The gut microbiota has a significant effect on host metabolism, partially through synthesis of short-chain fatty acids (SCFAs) ([@R71]; [@R55]; [@R35]). L cell hyperplasia was observed in germ-free (GF) and antibiotic-treated mice and could be suppressed by microbiota colonization and SCFAs ([@R77]; [@R3]; [@R82]). Similarly, we observed increased levels of *Gcg* and *Pyy* RNA ([Figure 6C](#F6){ref-type="fig"}) and serum GLP-1 in GF mice ([Figure 6D](#F6){ref-type="fig"}) compared with age-matched, conventionally housed specific pathogen-free (SPF) mice purchased from the same vendor. Immunostaining showed that global protein O-GlcNAcylation in the cytoplasm of colonocytes was dramatically inhibited in GF mice ([Figures 6E](#F6){ref-type="fig"} and [6F](#F6){ref-type="fig"}). We also treated C57BL/6 mice with multiple broad-spectrum antibiotics (ampicillin, gentamicin, metronidazole, neomycin, and vancomycin) to deplete the gut microbiota by oral gavage for 2 weeks ([@R27]; [@R53]). 16 s rRNA sequencing of fecal DNA confirmed that antibiotic treatment significantly reduced gut microbial diversity ([Figures S4A](#SD1){ref-type="supplementary-material"} and [S4B](#SD1){ref-type="supplementary-material"}). A substantial reduction in cytoplasmic levels of colonic O-GlcNAcylation was observed by immunostaining ([Figures 6G](#F6){ref-type="fig"} and [6H](#F6){ref-type="fig"}). Moreover, oral administration of a mixture of SCFAs (acetate, propionate, and butyrate) to mice largely restored the levels of O-GlcNAcylation in colonic epithelial cells ([Figures 6I](#F6){ref-type="fig"} and [S4C](#SD1){ref-type="supplementary-material"}). In addition, in cultured human intestinal Caco-2 cells, SCFA treatment was sufficient to raise protein O-GlcNAcylation levels ([Figure 6J](#F6){ref-type="fig"}). These data demonstrate that dietary nutrients and gut microbiota-derived SCFAs promote epithelial O-GlcNAcylation.

To test whether SCFAs suppress L cell function via O-GlcNAcylation, we treated ileal organoids with SCFAs and were able to observe repression of *Gcg* gene expression ([Figure 6K](#F6){ref-type="fig"}) and GLP-1 secretion ([Figure 6L](#F6){ref-type="fig"}) by SCFAs. Notably, treating cells simultaneously with the OGT inhibitor OSMI-1 could modestly reverse the repressive effect of SCFAs ([Figures 6K](#F6){ref-type="fig"} and [6L](#F6){ref-type="fig"}). It is worth noting that SCFAs inhibited GLP-1 secretion in wild-type and *Ngn3-Ogt* KO organoids ([Figure S4D](#SD1){ref-type="supplementary-material"}), indicating that OGT-independent pathways may also exist. Collectively, these results established O-GlcNAcylation as a molecular link between SCFAs and L cell function.

Microbial Disruption in *Vil-Ogt* KO Mice Contributes to Metabolic Improvement {#S8}
------------------------------------------------------------------------------

Intestinal epithelial O-GlcNAcylation not only responds to microbial cues but also modulates the gut microbiota; we recently demonstrated that OGT deficiency in intestinal epithelial cells is associated with microbial dysbiosis in mice ([@R83]). We then sought to determine whether the microbial changes in *Vil-Ogt* KO mice contribute to the systemic improvement in metabolism through fecal microbiota transplantation (FMT; [Figure S5A](#SD1){ref-type="supplementary-material"}). Microbiota-depleted or GF mice receiving FMT from *Vil-Ogt* KO mice gained significantly less body weight compared with their counterparts receiving FMT from wild-type (WT) mice ([Figures 7A](#F7){ref-type="fig"} and [7B](#F7){ref-type="fig"}). GF mice colonized with *Vil-Ogt* KO microbiota had much less fat composition ([Figure 7C](#F7){ref-type="fig"}) and reduced white adipose tissue (WAT) weight ([Figure 7D](#F7){ref-type="fig"}). Food intake ([Figure 7E](#F7){ref-type="fig"}) and locomotor activity ([Figure 7F](#F7){ref-type="fig"}) were similar in mice receiving FMT from WT and *Vil-Ogt* KO mice. Mice receiving *Vil-Ogt* KO FMT had a trending increase in respiratory exchange rate (RER; [Figures 7G](#F7){ref-type="fig"} and [7H](#F7){ref-type="fig"}), suggesting that glucose was used preferentially in these mice. Moreover, total energy expenditure, determined by heat production normalized to body weight ([Figure 7I](#F7){ref-type="fig"}) or adjusted to body weight using analysis of covariance (ANCOVA) ([Figure 7J](#F7){ref-type="fig"}), were increased remarkably in GF mice colonized with *Vil-Ogt* KO microbiota ([@R73]). Intriguingly, *Vil-Ogt* KO microbiota was able to marginally increase L cell numbers in recipient mice ([Figure S5B](#SD1){ref-type="supplementary-material"}). However, no substantial differences in random blood glucose ([Figure S5C](#SD1){ref-type="supplementary-material"}), oral glucose tolerance ([Figure S5D](#SD1){ref-type="supplementary-material"}), or insulin tolerance ([Figure S5E](#SD1){ref-type="supplementary-material"}) were observed in mice receiving FMT from WT or *Vil-Ogt* KO mice. These data indicate that changes in gut microbiota associated with *Vil-Ogt* KO are sufficient to drive L cell hyperplasia and reduced weight gain but not improvement in glucose metabolism.

DISCUSSION {#S9}
==========

Enteroendocrine L cells evolve multiple sensory mechanisms to detect different classes of luminal nutrients, including carbohydrates, lipids, and proteins ([@R21]). Recently, growing evidence has demonstrated that the gut microbiota influences intestinal homeostasis, glucose metabolism, and energy balance. Here we show that microbiota-derived SCFAs drive the levels of protein O-GlcNAcylation in intestinal epithelial cells, which serve as a negative regulator of L cell development and function. Loss of intestinal epithelial OGT and protein O-GlcNAcylation in mice results in L cell hyperplasia, improved metabolism, and microbial changes that contribute to metabolic health. Mechanistically, we determined that OGT-mediated FOXO1 O-GlcNAcylation suppresses *Ngn3* gene expression and inhibits differentiation of *Ngn3*^+^ EEC progenitors toward L cells *in vivo*.

In addition to aiding digestion and producing vitamins, the microbiota benefits the host through synthesis of SCFAs, including acetate, propionate, and butyrate ([@R71]). SCFAs bind to G-protein-coupled receptor 43 (GPR43, also known as free fatty acid receptor 2 \[FFAR2\]) and GPR41 (FFAR3) to regulate lipid and glucose metabolism ([@R12]). Butyrate and propionate are also potent inhibitors of histone deacetylases (HDACs) ([@R34]). More importantly, SCFAs are preferred metabolic substrates for intestinal epithelial cells ([@R12]); however, regulation of L cell development and function by SCFAs remains controversial. SCFAs have been shown to increase the number of L cells and induce PYY and GLP-1 secretion via GPR43 and GPR41 ([@R69]; [@R51]; [@R52]). However, intestinal KO of GPR43 and GPR41 does not alter glucose tolerance in diabetic animals ([@R67]), indicating that other receptors or sensing mechanisms for SCFAs might be involved. On the other hand, we and others have shown that GLP-1 transcription and secretion are more than 2-fold higher in GF mice than in conventionally raised mice. Importantly, intestinal colonization of the gut microbiota increases SCFAs and suppresses L cell function ([@R77]; [@R3]). More recently, [@R36] demonstrated that SCFAs, particularly propionate and butyrate, strongly increase *PYY* gene expression but slightly suppress *GCG* expression in human L cells. The reasons for these discrepancies among the reported results are still unclear but could be manifold: different assay systems used (cell lines versus organoids versus whole organisms, rodents versus humans), non-linear but biphasic responses to SCFA concentrations, shifting the differentiation of progenitors toward other EEC lineages (K, I, S, N, EC cells, etc.), divergent effects on L cells versus other mucosal cell types ([@R47], [@R48]), and complex interplay of SCFAs with other microbiota-derived metabolites and signals. Further studies are required to fully elucidate the microbial control of L cell development and function.

A large body of literature has shown that inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is generally associated with increased numbers of intestinal EECs and blood levels of gut hormones in humans ([@R78]). These enteroendocrine responses are thought to be involved in tissue repair and responsible for the reduced appetite and altered gut mobility associated with IBD. However, current IBD animal models that are induced by chemicals, including 2,4,6-trinitrobenzenesulfonic acid (TNBS) and dextran sulfate sodium (DSS), and genetic alterations (such as *Tcra*^−/−^ and *II2*^−/−^) cannot fully recapitulate the EEC alterations found in IBD patients ([@R78]). Our previous study has shown that levels of OGT and protein O-GlcNAcylation are reduced in inflamed intestinal epithelium in humans and that loss of intestinal epithelial OGT leads to microbial dysbiosis and intestinal inflammation in mice ([@R83]). In this study, we further show that OGT deficiency and associated microbial changes promote L cell differentiation and metabolic improvements. Proinflammatory cytokines, such as interferon γ (IFNγ) and tumor necrosis factor alpha (TNF-α) can act on intestinal stem/progenitors to drive alterations in EEC development. We then took advantage of organoid cultures and *Vil-Cre*^+^*;R26-rOGT* mice to modulate OGT levels without affecting the inflammatory gene program and were able to demonstrate that OGT directly inhibits L cell development. Taken together, these data indicate that defective protein O-GlcNAcylation can be a unifying pathogenic mechanism for microbial dysbiosis, intestinal inflammation, and EEC hyperplasia in IBD.

The *Ngn3*^+^ lineage in the intestine is essential for life because loss of EECs in mice impairs lipid absorption, alters glucose metabolism, and leads to frequent perinatal death ([@R42]). On the other hand, L cell hyperplasia, hormone hyper-secretion, and receptor agonism reduce food intake and ameliorate diabetes. Consistently, improved glucose metabolism and decreased body weight were observed in *Vil-Ogt* KO mice, in which EEC development was boosted. However, we only found very mild metabolic phenotypes in *Vil-Cre*^+^*;R26-rOGT* mice, in which L cell numbers were reduced. No significant changes in body weight, glucose tolerance, insulin tolerance, or gastrointestinal motility were observed in mice fed with normal chow or an HFD ([Figure 5](#F5){ref-type="fig"}; data not shown). This disparity could be due to the fact that L cells and GLP-1 levels were the primary targets of OGT overexpression in *Vil-Cre*^+^*;R26-rOGT* mice, whereas most EEC types were affected in *Vil-Ogt* KO mice. In fact, when gut-derived GLP-1 was genetically deleted in mice, relatively mild impairments of glucose tolerance and gastric emptying were noticed ([@R9]; [@R66]). Therefore, we do not think that the L cell hyperplasia observed in *Vil-Ogt* KO mice is enough to drive the substantial improvement in body weight and glucose metabolism. Microbial dysbiosis caused by *Vil-Ogt* KO could reduce the gain of body weight and fat when transplanted into GF mice. Thus, we speculate that GLP-1 hypersecretion and perturbed gut microbiota together result in the metabolic changes observed in *Vil-Ogt* KO mice. It is also possible that intestinal epithelial damage and inflammation caused by OGT deletion contribute to the evident weight loss in *Vil-Ogt* KO mice.

In summary, we show that O-GlcNAc signaling in intestinal epithelial cells, controlled by the gut microbiota and nutrient availability, suppresses *Ngn3* transcription via FOXO1 O-GlcNAcylation, restrains EEC development, and modulates whole-body energy and glucose metabolism. Therefore, harnessing the hexosamine synthetic pathway and protein O-GlcNAcylation can be a future strategy for treatment of obesity and diabetes.

STAR★METHODS {#S10}
============

RESOURCE AVAILABILITY {#S11}
---------------------

### Lead Contact {#S12}

Requests for further information and resources can be directed to the Lead Contact, Hai-Bin Ruan (<hruan@umn.edu>).

### Materials Availability {#S13}

Unique reagents generated in this study are available with a completed Material Transfer Agreement.

### Data and Code Availability {#S14}

The accession number for the 16S-seq data reported in this paper is Sequence Read Archive (SRA) repository: PRJNA644017.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S15}
--------------------------------------

### Animals {#S16}

*Ogt-floxed* mice ([@R64]) and *Rosa26-rOGT-floxed* on the C57BL/6 background were kindly provided by Dr. Xiaoyong Yang ([@R81]). *Villin-Cre* mice (stock no. 004586) and *Neurog3-Cre* mice (stock no. 006333) were purchased from the Jackson Laboratory. Germ free mice on the C57BL/6 background were purchased from Taconic Biosciences together with age and sex matched C57BL/6 SPF mice as control. 5 pairs of them were euthanized immediately upon arrival for tissue collection. 10 extra germ free mice were used in fecal microbiota colonization experiments. Homozygous floxed *Ogt*^*F/F*^ mice were bred to *Villin-Cre* and *Neurog3-Cre* mice to generate *Vil-Ogt* KO and *Ngn3-Ogt* KO mice, respectively. Homozygous floxed *Rosa26-rOGT* ^*F/F*^ mice were bred to *Villin-Cre* mice to generate *Vil-rOGT Tg* mice. 3-week to 4-month old mice were used for experiments. Age of mice in each experiment was specified in figure legends. All animals were kept on a 14 h: 10 h light: dark cycle in the animal facility at the University of Minnesota. Mice were group-housed unless otherwise mentioned, with free to access water and standard chow diet. All procedures involving animals were conducted within IACUC guidelines under approved protocols.

### Ileal organoid and Caco-2 cell culture {#S17}

Isolated ileal crypts were counted and cultured in Matrigel following a published protocol ([@R41]). Growth medium consists of Advanced DMEM/F12 with Glutamax, HEPES, Pen/Strep, 1x N2 supplement, 1x B27 supplement, EGF (50 ng/ml), Noggin (100 ng/ml), and R-spondin conditioned media. Organoids were maintained at 37°C and medium was changed every 3 days. Cultures were split weekly by mechanical disruption of organoids. Passage 3-5 were used for experiments. Organoids were treated with 50 μM OSMI-1, SCFAs (5 mM acetate, 1 mM butyrate and propionate) ([@R50]) and/or AS1842856 (Calbiochem, 1 μM) ([@R17]) for 2 days. Then medium was collected for GLP-1 measurement and organoids were subjected to RNA extraction or GLP-1 staining. Caco-2 cells were cultured as described previously ([@R45]). Differentiated Caco-2 cells were serum starved overnight and treated with SCFAs (8 μM each) for 24 h before being subjected to protein extraction.

METHOD DETAILS {#S18}
--------------

### Metabolic assays {#S19}

Body weights were monitored every week. Body composition was assessed using an EchoMRI system ([@R76]). For food intake measurement, mice were individually housed and food consumption was weighed every morning for 7 consecutive days. For the metabolic cage study, mice were first acclimated in metabolic chambers (Columbus Instruments), and then physical activity and energy expenditure were measured continuously for at least 2 days ([@R30]). For oral glucose-, and insulin-tolerance tests. 16 h fasted mice were given glucose (1.5 g/kg body weight) by gavage; 6 h fasted mice were injected with insulin (1 U/kg body weight) intraperitoneally. Tail-vein blood collected at the designated times was used to measure blood glucose level using a Contour Glucometer (Bayer). HOMA-IR was calculated as fasting insulin level x fasting glucose level. Serum insulin (EZRMI-13K) and active GLP-1 (EGLP-35K) were determined using ELISA kit (Millipore) following manufacture's instruction. To measure GI transit time, mice were fasted overnight and given a semiliquid methyl cellulose solution containing 0.1% Trypan blue by gavage. The time for expulsion of the fist blue feces pellet was determined as gastrointestinal transit time.

### Fecal microbiota colonization {#S20}

Donor mice were euthanized and ceca were aseptically removed immediately. The content was diluted 1:10 in a 50% glycerol/PBS solution and frozen at −80°C. On the day of inoculation, the cecal content was further diluted 1:5 in autoclaved PBS prior to oral gavage of 0.15 mL per mouse. Prior to inoculation, recipient animals were treated with a cocktail of broad-spectrum antibiotics to deplete gut microbiota ([@R27]; [@R53]). Specifically, animals having free access to autoclaved food and water were subjected to oral gavage daily for 14 days with 100 ul of autoclaved water supplemented with ampicillin (2 mg/ml), gentamicin (2 mg/ml), metronidazole (2 mg/ml), neomycin (2 mg/ml), and vancomycin (1 mg/ml). The germ-free recipient mice were inoculated immediately upon arrival at the University of Minnesota animal facility, and housed in SPF environment thereafter. A second inoculation was given 2 weeks later. Metabolic assays were carried out at indicated time points after transplantation.

### Short chain fatty acids (SCFAs) treatment {#S21}

Mice were treated with a cocktail of broad-spectrum antibiotics to deplete gut microbiota as mentioned above. Then sodium butyrate alone (3g/kg BW) or a mixture of sodium acetate, sodium propionate and sodium butyrate (1g of each SCFA/kg BW) were dissolved into saline and given by gavage 24h and 4 h before sacrifice.

### *In vivo* intestinal barrier function assays {#S22}

Mice were fasted for 2-h and orally gavaged with fluorescein isothiocyanate (FITC)-dextran (average molecular weight: 3,000--5,000, 0.6 mg/g; Sigma) diluted in PBS. Fluorescence intensity of plasma samples was measured (excitation 492 nm/emission 520 nm) 4 h after the gavage.

### 16S rRNA gene sequencing {#S23}

Total DNA in stool and cecal contents was extracted using the PowerFecal DNA Isolation Kit (Mo Bio). The V4 region of the bacterial 16S rRNA gene was amplified by triplicate PCR (F515/R806) using barcoded fusion primers. Samples were pooled in sets with a maximum of 96 samples in equal quantities. Paired-end sequencing of the amplicon library was performed on the Illumina MiSeq 300-bp paired-end platform at the University of Minnesota Genomics Center ([@R20]). A multistep bioinformatics analysis was performed using the QIIME 1.9.1 software, including filtering raw fastq files for primer and adaptor dimer sequences, removing contaminating host sequences and chimeric sequences, clustering sequences into operational taxonomic units (OTUs) using the open reference OTU calling method with the green genes 16S reference, and calculating alpha and beta diversity metrics. Linear discriminant analysis (LDA) effect size (LEfSe) method was used for microbial biomarker discovery ([@R63]).

### Chemicals, plasmids, transfection, and luciferase assay {#S24}

OSMI-1 (Sigma, 50 μM), 6-Ac-CAS (GlycoSyn, 10 μM), PUGNAc (Toronto Research Chemicals, 10 μM) were used when indicated. The Myc-hOGT plasmid was provided by Dr. Xiaochun Yu at the University of Michigan ([@R10]). *Ngn3-luc* was generated by inserting a \~4.1 kb promoter of the mouse *Ngn3* gene into the pGL3-basic vector. *IRE-luc* was generated by inserting the −1985 to −280 bp upstream of the mouse *Irs2* gene that contains two insulin-response elements (IREs) into the pGL3-basic vector. pCMV6-mNgn3-Myc-DDK (\#MR212139) was purchased from Origene. pCMV-FOXO1 (\#12148) was purchased from Addgene. pCMV-FOXO-4A was generated with the QuikChange XL II Site-Directed Mutagenesis Kit (Agilent). HepG2 and Caco-2 cells were transfected with expression plasmids, luciferase reporters, and β-galactosidase or Renilla-luciferase using Lipofectamine 3000 (Invitrogen) or FuGENE HD (Promega). Cells were lysed and luciferase and β-galactosidase enzyme activities were measured using kits from Promega. Relative luciferase activity was determined by normalizing to β-galactosidase or Renilla-luc activity ([@R56]; [@R76]).

### Histology, immunohistochemistry, and immunofluorescence {#S25}

Tissues and organoids were fixed in 10% neutral buffered formalin. Organoids were then embedded in 5% gelatin before paraffin embedding. Immunohistochemistry was carried out using Histostain-Plus 3^rd^ Gen IHC Detection Kit (Life technologies) following manufacturer's instruction. Antigen retrieval was performed in Citric buffer using a 2100 Retriever (Aptum Biologics). For immunofluorescence, tissue slides were blocked with 3% BSA, 0.2% TWEEN 20 in PBS, incubated with primary antibodies (1:100 to 1:200 dilution) overnight, and secondary antibodies (Alexa Fluor 488 anti-Rabbit IgG and anti-Mouse IgG, 1:400) for 1h. A Nikon system was used for fluorescence detection. For cell number quantification, 3-5 random fields per sample were captured. Stained cell specifically on the epithelium were counted. In the intestine, cell number was normalized to the number of crypt/villus units (ileum) or crypts (colon). In the organoid, cell number was normalized to nuclei number as indicated by DAPI staining. For the quantification of O-GlcNAcylation intensity in intestinal epithelium, the nucleus and cytoplasm region in the epithelium were selected and quantification was performed by FIJI.

### Immunoprecipitation and Western Blot {#S26}

Tissues were lysed in RIPA buffer containing proteinase inhibitors, protein phosphatase inhibitors and an OGA inhibitor. For immunoprecipitation, whole-cell lysates were incubated with and precipitated by anti-Flag beads (Millipore Sigma). Equal amounts of whole lysates or immunoprecipitation samples were electrophoresed on TGX precast gels (Bio-Rad) and transferred to nitrocellulose membrane. Membranes were incubated with primary antibodies at 4°C for overnight. Western blotting was visualized by using IRDye secondary antibodies and the Odyssey imaging system (LI-COR Biosciences).

### RNA and real time PCR {#S27}

Total RNA was extracted from mouse tissues and organoids using TRIzol reagent (Invitrogen). cDNA was reverse transcribed (BioRad) and amplified with SYBR Green Supermix (Bio-Rad) using a C1000 Thermal Cycler (Bio-Rad). All data were normalized to the expression of the *Rplp0* gene. Primer sequences are listed in [Table S2](#SD3){ref-type="supplementary-material"}.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S28}
---------------------------------------

N values ≥ 3 and ≥ 4 were used for *in vitro* and *in vivo* experiments, respectively. The statistical comparisons were carried out using two-tailed unpaired Student's t test and one-way or two-way ANOVA with indicated post hoc tests with Prism 7 (Graphpad). Differences were considered significant when p \< 0.05. Results are shown as mean ± SEM. \*, p \< 0.05; \*\*, p \< 0.01; \*\*\*, p \< 0.001.
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![Loss of OGT in the Intestinal Epithelium Promotes EEC Development\
(A and B) Expression of EEC marker genes in the ileum (A) and colon (B) of 2-month-old WT and *Vil-Ogt* KO male mice (n = 4--10).\
(C--E) Representative images (left) and quantified numbers (right) of GLP-1^+^ cells in the ileum (C, 133 and 92 crypt/villus units counted from 5 WT and 4 KO) and colon (D, 176 and 138 crypts counted from 5 WT and 5 KO) and PYY^+^ cells in the colon (E, 1,005 and 867 crypts counted from 5 WT and 4 KO) of 10-week-old WT and *Vil-Ogt* KO male mice.\
(F) Serum GLP-1 levels of WT (n = 9) and *Vil-Ogt* KO (n = 10) male mice at the age of 8--10 weeks.\
Data are represented as mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 by two-tailed unpaired Student's t test.](nihms-1620246-f0001){#F1}

![Improved Metabolism in *Vil-Ogt* KO Mice\
(A and B) Body weight (A) and body composition (B) of 7-week-old control (n = 6) and *Vil-Ogt* KO (n = 5) male mice.\
(C) Random blood glucose levels of control and *Vil-Ogt* KO male mice at the age of 4 (n = 2-5), 8 (n = 6), and 10 (n = 6) weeks.\
(D and E) Oral glucose tolerance test of 7-week-old control (n = 6) and *Vil-Ogt* KO (n = 4) male mice (D). Area under the curve of (D) is shown in (E).\
(F) Body weight of 9-week-old control (n = 11), heterozygous (n = 4), and homozygous (n = 5) *Vil-Ogt* KO female mice.\
(G and H) Oral glucose tolerance test of 10- to 14-week-old control (n = 11), heterozygous (n = 3), and homozygous (n = 5) *Vil-Ogt* KO female mice (G). Area under the curve of (G) is shown in (H).\
Data are represented as mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 by two-tailed unpaired Student's t test (A, B, and E), one-way ANOVA with post hoc Tukey's test (F and H), or two-way ANOVA with post hoc Sidak's test (C, D and G).](nihms-1620246-f0002){#F2}

![Protein O-GlcNAcylation Inhibits L Cell Development\
(A and B) Ileal organoids were treated with vehicle or OSMI-1 for 2 days, and then gene expression (A) and GLP-1 secretion to the medium (B) were determined (n = 3).\
(C) Schematic view of the *Rosa26-rOGT* locus and mating strategy to generate *Vil-Cre*^+^*;R26-rOGT* mice.\
(D) RNA levels of rat *Ogt* gene expression in the ileum and colon of 4-month-old control (n = 5) and *Vil-Cre*^+^*;R26-rOGT* (n = 4) mice.\
(E) Immunoblotting showing total protein O-GlcNAcylation, hemagglutinin (HA) tag, and OGT in the colon of control and *Vil-Cre*^+^*;R26-rOGT* mice.\
(F and G) Representative images (F) and quantified numbers of GLP-1^+^ L cells (G) in the colon of 4-month-old control (756 crypts of 5 mice) and *Vil-Cre*^+^*;R26-rOGT* (611 crypts of 4 animals) mice.\
(H) Serum GLP-1 levels of control and *Vil-Cre*^+^*;R26-rOGT* male mice (n = 3).\
(I) Growth curve of control (n = 8) and *Vil-Cre*^+^*;R26-rOGT* (n = 4) male mice fed normal chow.\
(J--L) Levels of blood glucose (J), blood insulin (K), and calculated HOMA-IR (L) of overnight-fasted control (n = 8) and *Vil-Cre*^+^*;R26-rOGT* (n = 4) male mice at the age of 4 months.\
Data are represented as mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 by two-tailed unpaired Student's t test.](nihms-1620246-f0003){#F3}

![O-GlcNAcylation Modulates the Transcriptional Activity of FOXO1\
(A) Transcriptional repressor of Ngn3-luciferase activity by OGT in Caco-2 cells (n = 6). RLU, relative luminescence unit.\
(B and C) Transcriptional activation of FOXO1 on the insulin-responsive element (*IRE*) with OGT coexpression (B) or OGA inhibition (C). Luciferase activity was normalized to co-transfected β-galactosidase (β-gal) activity in HepG2 cells (n = 4).\
(D) O-GlcNAcylation levels of WT- and 4A-FOXO1 expressed in 293 cells in the absence or presence of PUGNAc, an OGA inhibitor.\
(E) Changes in the transcriptional activation activity of FOXO1 on the *IRE*-luciferase (luc) reporter after co-expression with OGT in HepG2 cells (n = 4).\
(F) Transcriptional repression of Ngn3-luciferase activity by WT and 4A-FOXO1 in Caco-2 cells (n = 4--5).\
(G--J) Ileal organoids were treated with or without OSMI-1 in the presence or absence of AS1842856 for 2 days (n = 4). Expression of the *Nng3* (G), *Gcg* (H), and *Pyy* (I) genes and GLP-1 secretion into the medium (J) were determined. Log2 values of fold change (FC) after OSMI-1 treatment were calculated and plotted.\
Data are represented as mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 by two-tailed unpaired Student's t test (A and G--J), one-way ANOVA with post hoc Turkey's (B and E) or Dunnett's (F) test, or two-way ANOVA with post hoc Tukey's test (C).](nihms-1620246-f0004){#F4}

![Loss of OGT in the *Ngn3* Lineage Promotes L cell Development\
(A and B) Body weight (A) and random blood glucose (B) of WT and *Ngn3-Ogt* KO male mice at the indicated ages.\
(C) Representative images (left) and quantified numbers (right) of GLP-1^+^ L cells in the colon (187 and 235 crypts counted from 4 WT and 5 KO) of 3-week-old WT and *Ngn3-OGT* KO male mice.\
(D) Representative images (left) and quantified numbers (right) of PYY^+^ L cells in the colon (1,430 and 1,141 crypts counted from 4 WT and 5 KO) of 3-week-old WT and *Ngn3-Ogt* KO male mice.\
(E) Oral glucose tolerance test of 3-week-old (n = 4--5) *Ngn3-Ogt* KO male mice and their littermate controls after 4 h of fasting.\
(F) Ileal organoids from WT and *Ngn3-Ogt* KO male mice were cultured and collected to determine the expression of L cell marker genes by qRT-PCR (n = 4).\
(G) Secretion of GLP-1 from WT and *Ngn3-Ogt* KO organoids into the medium, determined by ELISA (n = 6).\
(H and I) Representative images (H) and quantified numbers (I) of GLP-1^+^ L cells in WT and *Ngn3-Ogt* KO organoids treated with vehicle or OSMI-1 (n = 3--4). See also [Table S1](#SD2){ref-type="supplementary-material"}.\
Data are represented as mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 by two-tailed unpaired Student's t test (C, D, F, and G) or two-way ANOVA with post hoc Sidak's test (B and E) or Tukey's test (I).](nihms-1620246-f0005){#F5}

![Regulation of L Cells and Protein O-GlcNAcylation by Gut Microbiota and Diet\
(A) Representative images of O-GlcNAc immunohistochemistry of the colon from *ad-libitum-fed,* overnight-fasted, and 4-h-refed mice (n = 3).\
(B) Immunoblotting of global protein O-GlcNAcylation in the colon of mice fed normal chow (NC; n = 4) or a high-fat diet (HFD; n = 5) for 2 months.\
(C) Expression of the *Gcg* and *Pyy* genes in isolated colonic epithelial cells from 2-month-old SPF and GF mice (n = 5).\
(D) GLP-1 levels in the serum of 2-month-old SPF and GF mice (n = 6), determined by ELISA.\
(E and F) Representative images (E) and quantification (F) of O-GlcNAc immunostaining of the colon from 2-month-old SPF and GF mice (n = 5).\
(G and H) Representative images (G) and quantification (H) of O-GlcNAc immunostaining of the colon from 2-month-old mice gavaged with H~2~O or antibiotics (ABX) for 2 weeks (n = 6).\
(I) Four-month-old mice were treated with saline or ABX for 1 week, followed by 2 doses (24 h and 4 h before sacrifice) of sodium butyrate (BUT) or SCFAs (3 g/kg body weight). Colon protein was extracted for immunoblotting with an anti-O-GlcNAc antibody.\
(J) Caco-2 cells were serum-starved overnight, treated with SCFAs (8 μM each) for 24 h, and subjected to O-GlcNAc immunoblotting.\
(K and L) Ileal organoids were treated with SCFAs and OSMI-1, as indicated, for 2 days. *Gcg* gene levels (K, n = 5--7) and GLP-1 secretion (L, n = 4--5) were determined.\
Data are represented as mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 by two-tailed unpaired Student's t test (C, D, F, and H) or one-way ANOVA with post hoc Dunnett's (K and L) test.](nihms-1620246-f0006){#F6}

![Gut Microbiota in *Vil-Ogt* KO Mice Promotes Metabolic Health\
(A) 10-week-old C57BL/6 male mice were subjected to ABX gavage for 2 weeks to deplete gut microbiota and then received FMT (on days 0 and 8) from wild-type (WT) or *Vil-Ogt* KO mice. Body weight gain was monitored for 5 weeks (n = 10).\
(B) Changes in body weight of 10-week-old GF male mice receiving FMT (on days 0 and 14) from WT or *Vil-Ogt* KO mice (n = 5).\
(C) Body composition analysis showing percentages of fat and lean mass in mice 2 months after FMT (n = 5).\
(D) Weight of intrascapular brown adipose tissue (BAT), inguinal WAT (iWAT), gonadal WAT (gWAT), liver, and quadriceps muscle in mice was determined 15 weeks after FMT (n = 5).\
(E) Average daily food intake of FMT mice over 15 days (10--11 weeks after FMT, n = 5).\
(F and J) Metabolic cage study of FMT mice (2 months after FMT, n = 5) showing daily locomotor activity (F), circadian RER (G), average RER during day and night (H), heat production normalized to body weight (I), and body weight-adjusted heat production (J) using ANCOVA.\
Data are represented as mean --SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 by two-tailed unpaired Student's t test (C, D) or two-way ANOVA with post hoc Sidak's test (A, B, H, and J).](nihms-1620246-f0007){#F7}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                     SOURCE                                 IDENTIFIER
  ------------------------------------------------------- -------------------------------------- ------------------------------------
  Antibodies                                                                                     
  Anti-O-GlcNAc antibody                                  Abcam                                  Cat\# ab2739; RRID: AB_303264
  Anti-GLP-1 antibody                                     Abcam                                  Cat\# ab22625; RRID: AB_447206
  Anti-ChgA antibody                                      Protein tech                           Cat\# 10529-1-AP; RRID: AB_2081122
  Anti-PYY antibody                                       Cell Signaling Technology              Cat\# 24895; RRID: AB_2798887
  Anti-HA tag antibody                                    Cell Signaling Technology              Cat\# 3724S; RRID: AB_1549585
  Anti-OGT antibody                                       Cell Signaling Technology              Cat\# 24083; RRID: AB_2716710
  Anti-β-Actin antibody                                   Millipore Sigma                        Cat\# A5441; RRID: AB_476744
  Anti-Flag M2 antibody                                   Millipore Sigma                        Cat\# F3165; RRID: AB_259529
  Anti-Tubulin antibody                                   Santa Cruz                             Cat\# SC-8035; RRID: AB_628408
  IRDye® 800CW Goat anti-Rat IgG Secondary Antibody       Li-Cor                                 Cat\# 925-32219; RRID: AB_2721932
  IRDye® 680RD Goat anti-Mouse IgG Secondary Antibody     LI-Cor                                 Cat\# 926-68070; RRID: AB_10956588
  Alexa Fluor 488 Donkey anti-Mouse Secondary Antibody    Invitrogen                             Cat\# R37114; RRID: AB_2556542
  Alexa Fluor 488 Donkey anti-Rabbit Secondary Antibody   Invitrogen                             Cat\# R37118; RRID: AB_2556546
  Chemicals, Peptides, and Recombinant Proteins                                                  
  Anti-FLAG® M2 Affinity Gel                              Millipore Sigma                        A2220
  TRIzol reagent                                          Invitrogen                             Cat\# 15596018
  iTaq Universal SYBR Green Supermix                      Bio-Rad                                Cat\# 172-5124
  RIPA buffer                                             Millipore Sigma                        Cat\# 20-188
  Trypan blue solution                                    Millipore Sigma                        Cat\# 501613349
  Matrigel                                                Corning                                354230
  Advanced DMEM/F12                                       Thermo Scientific                      Cat\# 12634-010
  EGF                                                     Peprotech                              CaN/At \# AF-100-15
  Noggin                                                  Peprotech                              Cat\# 250-38-100ug
  R-spondin 1 conditioned medium                          In-house production                    N/A
  Y-27632                                                 Millipore Sigma                        Cat\# Y0503
  HEPES                                                   Thermo Scientific                      Cat \# 15630-56
  Glutamax                                                Thermo Scientific                      Cat \# 35050-038
  Penicillin/Streptomycin                                 Thermo Scientific                      Cat \# 15140-122
  B-27 supplement (50X)                                   GIBCO                                  Cat \# 17504-044
  N2 supplement (100 X)                                   GIBCO                                  Cat \# 17502-048
  PBS                                                     Corning                                Cat \# 21040CV
  Vectashield Mounting Medium with DAPI                   Vector Laboratories                    Cat \# H-1500
  Insulin                                                 Millipore Sigma                        Cat\# 91077C
  Ampicillin Sodium Salt                                  Teknova                                Cat\# A9510
  Gentamicin Sulfate                                      Teknova                                Cat\# G3610
  Metronidazole                                           Spectrum                               Cat\# M1511
  Neomycin Sulfate                                        Amresco                                Cat\# 0558
  Vancomycin                                              VWR                                    Cat\# 0990-5G
  Sodium butyrate                                         Millipore Sigma                        Cat\# ARK2161
  Sodium acetate                                          Millipore Sigma                        Cat\# S1429
  Sodium propionate                                       Millipore Sigma                        Cat\# P5436
  AS1842856                                               Calbiochem                             Cat\# 344355
  6-Ac-CAS                                                GlycoSyn                               Cat\# FC-002
  PUGNAc                                                  Toronto Research Chemicals             Cat\# A157250
  OSMI-1                                                  Millipore Sigma                        Cat\# SML1621
  FITC-Dextran                                            Millipore Sigma                        Cat\# FD4
  Lipofectamine 2000 Transfection Reagent                 Invitrogen                             Cat\# 11668019
  FuGENE® HD Transfection Reagent                         Promega                                Cat\# E2311
  Critical Commercial Assays                                                                     
  Histostain-Plus 3rd Gen IHC Detection Kit               Life technologies                      Cat\# 859073
  Rat/Mouse Insulin ELISA kit                             Millipore Sigma                        Cat\# EZRMI-13K
  Glucagon Like Peptide-1 (Active) ELISA kit              Millipore Sigma                        Cat\# EGLP-35K
  PowerFecal DNA Isolation Kit                            Mo Bio                                 Cat\# 12830-50
  Deposited Data                                                                                 
  16S sequencing                                          This paper                             BioProject ID: PRJNA644017
  Experimental Models: Cell Lines                                                                
  Human: HepG2                                            ATCC                                   HB-8065
  Human: Caco-2                                           ATCC; share by Dr. Daniel A. Vallera   HTB-37
  R-spondin stable cell line                              from Dr. Noah Shroyer                  N/A
  Experimental Models: Organisms/Strains                                                         
  Mouse: Ogt-floxed mice                                  Jackson Laboratory                     004860
  Mouse: Rosa26-rOGT-floxed mice                          [@R81]                                 N/A
  Mouse: Villin-Cre                                       Jackson Laboratory                     \# 004586
  Mouse: Neurog3-Cre mice                                 Jackson Laboratory                     \# 006333
  Mouse: Vil-Ogt KO mice                                  This paper                             N/A
  Mouse: Ngn3-Ogt KO mice                                 This paper                             N/A
  Mouse: Vil-rOGTTg mice                                  This paper                             N/A
  Mouse: SPF C57BL/6 mice                                 Taconic Biosciences                    B6-M MPF
  Mouse: Germ-free C57BL/6 mice                           Taconic Biosciences                    B6-M GF
  Oligonucleotides                                                                               
  [Table S2](#SD3){ref-type="supplementary-material"}     This paper                             N/A
  Recombinant DNA                                                                                
  Myc-hOGT plasmid                                        [@R10]                                 N/A
  Ngn3-luc plasmid                                        This paper                             N/A
  IRE-luc plasmid                                         This paper                             N/A
  pCMV6-mNgn3-Myc-DDK                                     Origene                                Cat\# MR212139
  pCMV-FOXO1                                              Addgene                                Cat\# 12148
  pCMV-FOXO-4A                                            This paper                             N/A
  β-galactosidase                                         [@R56]                                 N/A
  Renilla-luciferase                                      [@R76]                                 N/A
  Software and Algorithms                                                                        
  Graphpad Prism 7                                        <https://www.graphpad.com>             N/A
  FIJI                                                    <https://imagej.net/Fiji>              N/A
  Other                                                                                          
  Contour glucometer                                      Bayer                                  Cat\# 9545C
  Blood glucose test strips                               Bayer                                  Cat\# 7097C

###### Highlights

-   O-GlcNAcylation in intestinal epithelial cells suppresses L cell differentiation

-   FOXO1 O-GlcNAcylation inhibits *Ngn3* transcription

-   SCFA-dependent O-GlcNAc is required for microbial regulation of L cell function

-   Microbial dysbiosis in OGT-deficient mice contributes to improved metabolism
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